O29 Efficacy and safety of mirikizumab in patients with ulcerative colitis: phase 3 LUCENT-1 study results

IntroductionMirikizumab (miri) is a humanized, IgG4 monoclonal antibody directed against the p19 subunit of IL-23, a key mediator in the pathogenesis of IBD. We assessed the induction efficacy and safety of miri with a Phase 3, multi-center, randomized, parallel-arm, double-blind, placebo (PBO)-cont...

Ausführliche Beschreibung